This grant is a new Cancer Center Support Grant application from the Vincent T. Lombardi Cancer Research Center (LCRC). The LCRC is a previously identified comprehensive cancer center of the National Cancer Institute. It previously enjoyed continuous funding as a cancer center by the NCI until its most recent renewal was approved but not funded. The current submission, a new application, represents the product of a complete reorganization of the LCRC with major new leadership, new personnel and new program building on an existing institutional framework. The LCRC, initially established in 1970 by the trustees of the University, is a comprehensive cancer center which is designed to promote interdisciplinary clinical and laboratory research throughout the University. It consists of twelve major program areas. Eight of these programs are multi-disciplinary involving laboratory and clinical investigations and four of the programs are primarily laboratory in nature. The multidisciplinary programs are AIDS, Breast Cancer, Experimental Therapeutics, Experimental Hematology and Bone Marrow Transplantation, Gastrointestinal Malignancies, Genitourinary Malignancies, Gynecologic Oncology, and Radiation Oncology. The four basic science research programs are ADP-Ribosylation and Repair of DNA Damage, Control of Invasion and Metastasis, Growth Regulation of Cancer, and Viral Oncology. The twelve programs as well as other investigations within the Cancer Center receive substantial support from seven shard basic resources that have been established by the Center. These include Recombinant Technology Peptide Synthesis and Sequencing, Flow Cytometry, Microscopy and Morphology, Animal Facility for Nude Mice Experimentation, Tumor Imaging, Biostatistics, and a Clinical Research Management Facility. The University has committed significant resources to the renewal and rededication of the Cancer Center including major salary support, discretionary authority for disbursement of funds, major salary support, discretionary authority for disbursement of funds, major renovation of space, and responsibility for coordinating all clinical and laboratory cancer related activities on the campus. The LCRC faculty of 136 receive over 8 million dollars annually in extramural support with more than 11 million dollars in grants pending. The achievements of the Cancer Center in the past have been substantial and the potential for the future of current programs and initiatives is extremely promising.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA051008-01
Application #
3101872
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1990-09-30
Project End
1993-04-30
Budget Start
1990-09-30
Budget End
1991-04-30
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Georgetown University
Department
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59

Showing the most recent 10 out of 1120 publications